Will Medicare Price Negotiation Stop Post-Approval R&D?

Infographic: One of the more prominent arguments against the Medicare drug price negotiation program is that by limiting the number of years that products can be marketed before price caps are imposed, the scheme discourages development of additional indications.

stop sign
• Source: Shutterstock

 (Also see "Medicare Price Setting And The Value Of Post-Approval R&D Spending" - In Vivo, 29 November, 2023.)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from 2024

More from Outlook

Investor Optimism Ahead As Big Medtech Proves ‘It’s All About Value’

 
• By 

Pressure to exploit connected care functionality is accelerating the shift in care delivery away from the inpatient setting. Medtechs are reshaping to maximize faster-growth opportunities.

2024’s Busiest Dealmakers: Novartis Laps The Field, While Lilly, Sanofi Keep Busy

 
• By 

Nine biopharma companies made 12 or more deals, with Novartis inking 21 deals and leading M&A activity. Roche, meanwhile, spent little up front but maintained a hectic pace with 12 alliances.

Big Pharma Headcounts: Obesity Leaders Bulk Up As Others Go Lean

 

As Eli Lilly and Novo Nordisk reap the blockbuster rewards of their rival obesity therapies the companies are also bulking up their organizations to make the most of the phenomenal rise of the GLP-1 class.